Early results of chemotherapy with retroperitoneal lymph node dissection for isolated retroperitoneal recurrence of upper urinary tract urothelial carcinoma after nephroureterectomy

Canadian Journal of Urology

Volumn 17, Issue 3, 2010, Pages 5184-5189

  Childs, M Adam ^a   Wood, Christopher G ^a   Spiess, Philippe E ^a   Debiane, Labib G ^a   Hernandez, Mike ^a   Matin, Surena F ^a   Millikan, Randall E ^a   Siefker Radtkie, Arlene ^a   Scott, Shellie M ^a   Pisters, Louis L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Metastasis; Survival; Upper tract; Urothelial carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; HUMAN; KIDNEY TUMOR; LYMPHADENECTOMY; MALE; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; RETROPERITONEAL TUMOR; RETROPERITONEUM; RETROSPECTIVE STUDY; SECOND CANCER; TIME; TRANSITIONAL CELL CARCINOMA; URETER; URETER TUMOR;

ADULT; AGED; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; HUMANS; KIDNEY NEOPLASMS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; NEPHRECTOMY; RETROPERITONEAL NEOPLASMS; RETROPERITONEAL SPACE; RETROSPECTIVE STUDIES; TIME FACTORS; URETER; URETERAL NEOPLASMS;

EID: 79958070788     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Genega EM, Porter CR. Urothelial neoplasms of the kidney and ureter. An epidemiologic, pathologic, and clinical review. Am J Clin Pathol 2002;117 (Suppl):S36.
2. Sagalowsky AI, Jarrett TW. Management of urothelial tumors of the renal pelvis and ureter. In: Campbell-Walsh Urology 2007, 9Th edition, Volume 2. Ed(s) LR Kavoussi, AC Novick, AW Partin, CA Peters, AJ Wein. Saunders Elsevier: Philadelphia PA, 1653-1685, 2007.
3. Huben RP, Mounzer AM, Murphy GP. Tumor grade and stage as prognostic variables in upper tract urothelial tumors. Cancer 1988;62(9):2016-2020.
4. Batata MA, Whitmore Jr WF, Hilaris BS, Tokita N, Grabstald H. Primary carcinoma of the ureter: a prognostic study. Cancer 1975;35(6):1626-1632.
5. Hall MC, Womack S, Sagalowsky AI, Carmody T, Ericstad MD, Roehrborn CG. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 1998;52(4):594-601.
6. Calabro F, Sternberg CN. High-risk metastatic urothelial cancer: chances for cure? Curr Opin Urol 2002;12(5):441-448.
7. Brausi MA, Gavioli M, De Luca G, Verrini G, Peracchia G, Simonini G, Viola M. Retroperitoneal lymph node dissection (RPLD) in conjunction with nephroureterectomy in the treatment of infiltrative transitional cell carcinoma (TCC) of the upper urinary tract: impact on survival. Eur Urol 2007; 52(5):1414-1418.
8. Kondo T, Nakazawa H, Ito F, Hashimoto Y, Toma H, Tanabe K. Impact of the extent of regional lymphadenectomy on the survival of patients with urothelial carcinoma of the upper urinary tract. J Urol 2007;178(4):1212-1217.
9. Lerner SE, Blute ML, Richardson RL, Zincke H. Platinum- based chemotherapy for advanced transitional cell carcinoma of the upper urinary tract. Mayo Clinic Proceedings 1996;71(10): 945-950.
10. Roscigno M, Shariat SF, Margulis V, Karakiewicz P, Remzi M, Kikuchi E, Langner C, Lotan Y, Weizer A, Bensalah K, Raman JD, Bolenz C, Guo CC, Wood CG, Zigeuner R, Wheat J, Kabbani W, Koppie TM, Ng CK, Suardi N, Bertini R, Fernandez MI, Mikami S, Isida M, Michel MS, Montorsi F. Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol 2009;181(6):2482-2489.
11. Sweeney P, Millikan RE, Donat, M, Wood CG, Sieker-Radtke A, Pettaway CA, Grossman HB, Dinney CPN, Swanson DA, Pisters LL. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol 2003;169(6):2113-2117.
12. Abe T, Shinohara N, Harabayashi T, Sazawa A, Maruyama S, Nomomura K. Impact of multimodal treatment on survival in patients with metastatic urothelial cancer. Eur Urol 2007;52(4):1106-1113.
13. Cowles RS, Johnson DE, McMurtrey MJ. Long-term results following thoracotomy for metastatic bladder cancer. Urology 1982;20(4):390-392.
14. Dodd PM, McCaffrey JA., Herr H, Mazunder M, Bacik J, Higgins G, Boyle MG, Scher HI, Bajorin DF. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol 1999; 17(8):2546-2552.
15. Herr HW, Donat SM, Bajorin DF. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol 2001;165(3):811-814.
16. Lehmann J, Suttmann H, Albers P, Volkmer B, Gschwend JE, Fechner G, Spahn M, Heidenreich A, Odenthal A, Seif C, Nurnberg N, Wulfing C, Greb C, Kaible T, Grimm MO, Fieseler CF, Krege S, Retz M, Schulte-Baukloh H, Gerber M, Hack M, Kamradt J, Stockle M. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol 2009;55(6):1293-1299.
17. Miller RS, Freiha FS, Reese JH, Ozen H, Torti FM. Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium. J Urol 1993;150(1):65-69.
18. Siefker-Radtke AO, Walsh GL, Pisters LL, Shen YU, Swanson DA, Logothetis CJ, Millikan RE. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol 2004;171(1):145-148.
19. Thompson IM, Genitourinary Sites. In: AJCC Cancer Staging manual, 6th edition. ed(s) FL Greene, DL Page, ID Fleming. Springer: New York, NY, 301-30, 2002.
20. Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol 2002;167(3):1295-1298.
21. Abdel-Latif M, Abol-Enein H, El-Baz M, Ghoneim MA. Nodal involvement in bladder cancer cases treated with radical cystectomy: incidence and prognosis. J Urol 2004;172(1):85-89.
22. Konety BR, Joslyn SA, O'Donnell MA. Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base. J Urol 2003;169(3):946-950.
23. Leissner J, Hohenfellner R, ThuroffJW. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int 2000;85(1):817-823.
24. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Ragharian D, Skinner DG. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19(3):666-675.
25. Komatsu H, Tanabe N, Kubodera, S, Maezawa H, Ueno A. The role of lymphadenectomy in the treatment of transitional cell carcinoma of the upper urinary tract. J Urol 1997;157(5):1622-1624.
26. Miyake H, Hara I, Gohji K, Arakowa S, Kamidono S. The significance of lymphadenectomy in transitional cell carcinoma of the upper urinary tract. Br J Urol 1998;82(4):494-498.
27. Roscigno M, Cozzarini C, Bertini R, Scattoni V, Freschi M, Da Pozzo LF, Briganti A, Gallina A, Capitanio U, Columbo R, Giorgio G, Montorsi F, Rigatti P. Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract. Eur Urol 2008;53(4): 794-802.